We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 183

AbbVie Files Suit Against Sandoz Alleging Infringement of Two Humira-Related Patents
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 14 2018

On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz International GMBH


Using Theses as Prior Art at the PTAB
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 7 2018

Based on recent Patent Trial and Appeal Board (“PTAB” or “the Board”) decisions, the best practice to establish an academic thesis as a printed


WesternGeco Could Lead To Cases Against Foreign Suppliers
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 3 2018

On June 22, 2018, the U.S. Supreme Court held in WesternGeco LLC v. Ion Geophysical Corp. that the plaintiff could recover foreign lost profit damages


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • August 2 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


PTAB Institutes a Second IPR on Rituxan-related ’821 Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 1 2018

The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan (rituximab), a monoclonal


First IPR Against Biogen’s ’172 Patent Instituted After Multiple Attempts
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 25 2018

U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s lymphoma, has been


USPTO Incentive Policies Influence Patentability Decisions
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 23 2018

U.S. Patent and Trademark Office human resource policies influence patentability decisions, potentially increasing the rate at which examiners issue


Federal Circuit: No Tribal Sovereign Immunity in IPRs
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 23 2018

On Friday, July 20, 2018, the Federal Circuit, in a precedential opinion, affirmed the Patent Trial and Appeal Board's ("PTAB's") decision that tribal


Genentech Files Suit Alleging Eli Lilly’s Taltz Product Infringes a Newly Issued Genentech Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 16 2018

Taltz was first approved in the United States in 2016 and is currently approved for the treatment of adults with active psoriatic arthritis or


Genentech Files Two New Lawsuits Against Celltrion Alleging Infringement of Patents Related to Rituxan and Herceptin
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 16 2018

As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents covering Rituxan